Sugi Predict

Sugi Predict / Targets / FGF2

FGF2

Fibroblast growth factor 2 · P09038 · FGF2 on Sugi Atlas →

10,017 patent compounds predicted against FGF2, 5,436 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3804442 SCHEMBL3804442 0.62 11/20
SCHEMBL2058821 SCHEMBL2058821 0.58 8/20
SCHEMBL2059338 SCHEMBL2059338 0.53 8/20
Potassium Ion Potassium Ion (SCHEMBL380009) 0.31 8/20
Water Water (SCHEMBL6357796) 0.31 8/20
SCHEMBL3691749 SCHEMBL3691749 0.68 7/20
SCHEMBL1787297 SCHEMBL1787297 0.50 7/20
Sucrosofate Sucrosofate (SCHEMBL3086839) 0.48 7/20
SCHEMBL3391119 SCHEMBL3391119 0.60 6/20
SCHEMBL728827 SCHEMBL728827 0.60 6/20
SCHEMBL4895055 SCHEMBL4895055 0.59 6/20
SCHEMBL4902478 SCHEMBL4902478 0.59 6/20
SCHEMBL2059166 SCHEMBL2059166 0.56 6/20
SCHEMBL3135361 SCHEMBL3135361 0.55 6/20
SCHEMBL3135366 SCHEMBL3135366 0.55 6/20
SCHEMBL875405 SCHEMBL875405 0.52 6/20
SCHEMBL883756 SCHEMBL883756 0.49 6/20
SCHEMBL3003403 SCHEMBL3003403 0.46 6/20
SCHEMBL4180806 SCHEMBL4180806 0.69 5/20
Sucrosofate Sucrosofate (SCHEMBL2063889) 0.65 5/20

Clinical trials — most relevant to FGF2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of Platelet Rich Fibrin Matrix as Regenerative Material in Intraosseous Defects PHASE3COMPLETED
Allograft Adipose Injectable for Vocal Fold Paralysis PHASE3UNKNOWN
Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2 PHASE3COMPLETED
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE3COMPLETED
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors PHASE2WITHDRAWN
Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders PHASE1/PHASE2COMPLETED
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 PHASE2COMPLETED
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT PHASE2WITHDRAWN
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. PHASE1/PHASE2ENROLLING_BY_INVITATION
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer PHASE2COMPLETED
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome PHASE1/PHASE2COMPLETED
In-office Repair of Chronic Tympanic Membrane Perforations PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial PHASE2COMPLETED
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease PHASE2UNKNOWN
FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma PHASE1COMPLETED
Safety Study of Topical Human FGF-1 for Wound Healing PHASE1UNKNOWN
Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Gingival Recession Defects EARLY_PHASE1COMPLETED
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis nanUNKNOWN
Role of FGF21 in Breast Cancer nanNOT_YET_RECRUITING
Importance of Neurogenic Inflammation in the Angiogenic Response of the Dental Pulp as a Defensive Response nanCOMPLETED
Correlation of Plasma Endothelial Cell Activity With Cardiovascular Events in Patients With Diabetes Mellitus Type 2 nanCOMPLETED
Platelet Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome (HiPPO Trial) nanCOMPLETED
Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars. nanCOMPLETED
Evaluation of Different Materials in Pulpotomy of Primary Molars nanUNKNOWN
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients nanUNKNOWN
PRF Growth Factors Levels in Diabetic Patients With Chronic Periodontitis nanCOMPLETED
Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FGF2 binder may also engage these)

ProteinNameSimilarity
Q5IS69 — 1.000 Q5IS69 →
VEGFA Vascular endothelial growth factor A, long form 0.984 landscape →
Q00731 — 0.981 Q00731 →
Q60487 — 0.974 Q60487 →
Q7YR31 — 0.972 Q7YR31 →
P28361 — 0.972 P28361 →
Q9H2S5 — 0.972 Q9H2S5 →
Q5TM52 — 0.972 Q5TM52 →
Q69ZB3 — 0.972 Q69ZB3 →
O76081 — 0.970 O76081 →
PGF Placenta growth factor 0.970 landscape →
LMTK3 Serine/threonine-protein kinase LMTK3 0.970 landscape →
Q12870 — 0.969 Q12870 →
Q92914 — 0.969 Q92914 →
P0C7X2 — 0.968 P0C7X2 →
TESK1 Dual specificity testis-specific protein kinase 1 0.968 landscape →
P79348 — 0.968 P79348 →
A6NIN4 — 0.968 A6NIN4 →
O75638 — 0.968 O75638 →
Q8K3V5 — 0.968 Q8K3V5 →
Q96JP2 — 0.967 Q96JP2 →
P15863 — 0.967 P15863 →
Q1ZZU3 — 0.967 Q1ZZU3 →
Q7RTU5 — 0.967 Q7RTU5 →
Q8K4Z2 — 0.967 Q8K4Z2 →
Q9DE09 — 0.967 Q9DE09 →
A2CE44 — 0.967 A2CE44 →
A0A494C0N9 — 0.966 A0A494C0N9 →
Q8NAU1 — 0.966 Q8NAU1 →
Q8WTX9 — 0.966 Q8WTX9 →